What is Supernus Pharmaceuticals's interest expense?

Supernus Pharmaceuticals (SUPN) reported interest expense of $0 in Q4 2025.

What is the long-term trend for Supernus Pharmaceuticals's interest expense?

Over 3 years (2022 to 2025), Supernus Pharmaceuticals's interest expense has grown at a -100.0% compound annual growth rate (CAGR), from $7.07M to $0.

What does interest expense mean?

Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.

Supernus Pharmaceuticals SUPN Interest Expense

Discontinued — last reported Q4 '25

Interest Expense at other companies

Zevra Therapeutics, Inc.ZVRA

$1.71M-13.1%

Acadia PharmaceuticalsACAD

$8.06M+1.9%

Amneal Pharmaceuticals, Inc.AMRX

-$53.36M+6.3%

XER

Xeris Biopharma Holdings, Inc.XERS

$6.88M-5.8%

Jazz PharmaceuticalsJAZZ

-$39.9M+25.7%

Collegium Pharmaceutical, Inc.COLL

$15.86M-23.7%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.6B+43.7%

Enterprise value$2.45B+42.2%

P/S3.3×+0.6×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The official record: Supernus Pharmaceuticals’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's interest expense?: Supernus Pharmaceuticals (SUPN) reported interest expense of $0 in Q4 2025.
What is the long-term trend for Supernus Pharmaceuticals's interest expense?: Over 3 years (2022 to 2025), Supernus Pharmaceuticals's interest expense has grown at a -100.0% compound annual growth rate (CAGR), from $7.07M to $0.
What does interest expense mean?: Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.